Preventing the Spread of Infection by Increasing Production of PCR Test Kits and Mobile X-ray Systems
First written in FY2020. 6 of 14 entries say "Advanced", first in FY2021-Q1. Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024DroppedAnnual report
「In the medtech field, the company is advancing the provision of solutions that combine component analysis and image analysis technologies to support healthy longevity, while also conducting research and development related to infectious diseases and Alzheimer’s disease in collaboration with partners.」
The previous measures that explicitly prioritized PCR testing reagent kits and responses to COVID-19 are no longer stated, with the focus shifting to healthcare and medtech generally, infectious disease research and dementia research. - FY2024-Q1SoftenedAnnual report
「In Japan, liquid chromatographs increased in the healthcare field, while overseas, liquid chromatographs, mass spectrometry systems and gas chromatographs increased in healthcare, green fields and academia. The performance of Shimadzu Diagnostics Corporation also contributed.」
The contribution to results has shifted from being centered on infection-control products to a composition centered on core products for healthcare, Green and academia, as well as contributions from 島津ダイアグノスティクス, while COVID-related products declined. - FY2023-Q3RestatedAnnual report
「In addition to increased sales of COVID-19 detection reagent kits in Japan as the number of infections rose, making Nissui Pharmaceutical Co., Ltd. a consolidated subsidiary also contributed to performance.」
For infectious disease control, the disclosure noted an increase in diagnostic reagent kits accompanying the rise in domestic infections, as well as a contribution to results from the consolidation of Nissui Pharmaceutical as a subsidiary. - FY2023-Q2ReframedAnnual report
「In Japan, sales of novel coronavirus detection reagent kits increased as the number of infections rose.」
Where a decline in domestic detection reagent kits was reported in the previous quarter, sales turned to an increase in the current quarter as the number of infected people rose. - FY2023-Q1ReframedAnnual report
「In Japan, revenue declined due to a decrease in COVID-19 detection reagent kits.」
The rollout of diagnostic reagent kits for the infectious disease control business continues, but its contribution to performance in Japan has declined as the number of infections has fallen. - FY2022AdvancedAnnual report
「In Japan, the company will supply test kits for conditions other than the novel coronavirus for the more than 1,300 fully automated PCR testing systems delivered, to promote their effective use. It is developing a network system to manage test results and testing histories, advancing collaboration with the government and local authorities, and further promoting the creation of systems for infectious-disease control. 株式会社AdvanSentinel, established with Shionogi & Co.,Ltd., will launch a new wastewater-monitoring initiative as part of infectious-disease control.」
Building on a track record of delivering more than 1,300 fully automated PCR testing systems, initiatives have expanded to kits for other infectious diseases, testing data management, collaboration with governments and local authorities, and wastewater monitoring. - FY2022-Q3RestatedAnnual report
「COVID-19 detection reagent kits and fully automated PCR testing systems contributed to performance.」
Detection reagent kits and fully automated PCR testing systems developed and sold as measures against infectious diseases continued to contribute to results. - FY2022-Q2RestatedAnnual report
「Sales of novel coronavirus detection reagent kits and fully automated PCR testing systems also increased.」
The company continues to report increases in detection reagent kits and fully automated PCR testing systems developed and sold as measures against infectious diseases. - FY2022-Q1AdvancedAnnual report
「Reagent kits for detecting COVID-19 and fully automated PCR testing systems also contributed to results, primarily in Japan.」
It has been confirmed that the reagent kits and fully automated PCR testing systems developed and sold as measures against infectious diseases contributed to results, primarily in Japan. - FY2021AdvancedAnnual report
「In 2020, the company positioned infection control as an urgent and important social issue and pursued businesses that contributed to preventing the spread of infection, including the development and sale of COVID-19 detection reagent kits and fully automated PCR testing equipment for clinics, support for establishing PCR testing centers at universities, and wastewater virus testing services to help prevent cluster outbreaks. Going forward, it will work to establish new testing methods, including breath-based virus testing and initiatives to predict and prevent severe disease. It will also expand overseas sales of detection reagent kits and fully automated PCR testing equipment.」
Infectious disease control measures have expanded from the development, sale and increased production of PCR-related products to support for university testing centers, wastewater testing, breath testing, prediction of severe disease, and overseas expansion. - FY2021-Q3AdvancedAnnual report
「The novel coronavirus detection reagent kits and the fully automated PCR testing system for clinics launched in November 2020 contributed to measures to combat infectious diseases.」
Regarding measures to address infectious diseases, specific progress was reported, including the launch in November 2020 of a fully automated PCR testing system for clinics, which, together with detection reagent kits, contributed to infectious disease control. - FY2021-Q2AdvancedAnnual report
「The healthcare fields of pharmaceuticals and food remained solid, while novel coronavirus detection reagent kits were widely used domestically for infection diagnosis and contributed to results.」
The report describes specific progress regarding the detection reagent kits whose development and increased production began in the previous fiscal year, noting that they were used extensively in Japan for infection diagnosis and contributed to performance. - FY2021-Q1AdvancedAnnual report
「The new novel coronavirus detection reagent kit for PCR testing launched in April ramped up rapidly and contributed to results, while environmental equipment also increased in Japan and overseas.」
Regarding the PCR test reagent kits for which development, sales and increased production began in the previous fiscal year, specific progress was reported: following their launch in April 2020, sales ramped up rapidly and contributed to results. - FY2020First statedAnnual report
「We are currently developing and selling a PCR test reagent kit capable of determining in a short time whether a person is infected with COVID-19, and are urgently working to establish a substantially expanded production system. We are also working to increase production of mobile X-ray systems used to diagnose pneumonia. The Shimadzu Group will give top priority to activities that help prevent the spread of COVID-19.」
Development, sales, and substantial production increases for PCR test reagent kits, together with increased production of mobile X-ray systems, were identified as new top-priority COVID-19 response measures.